Discovering Effective Treatments & A Cure for Fragile X Syndrome

Your support enables FRAXA Research Foundation to fund groundbreaking research and life-changing clinical trials.

Discovering Effective Treatments & A Cure for Fragile X Syndrome

How Does FRAXA Help?

FRAXA’s mission is to find effective treatments and ultimately a cure for Fragile X syndrome. We directly fund research grants and fellowships at top universities around the world. We partner with biomedical and pharmaceutical companies, large and small, to bridge the gap between research discoveries and actual treatments.

Every member of our staff and Board of Directors is a parent of one or more children with Fragile X, making our commitment to this cause deeply personal.

Treatments for Fragile X are likely to help people affected by autism, Alzheimer’s, and other brain disorders.

What is Fragile X Syndrome?

Fragile X syndrome (FXS) is the most common inherited cause of autism and intellectual disabilities. It affects 1 in 4,000 boys and 1 in 8,000 girls worldwide.

Fragile X syndrome occurs when a single gene on the X chromosome shuts down. This gene makes a protein needed for normal brain development. In FXS it does not work properly, the protein is not made, and the brain does not develop as it should.

Symptoms of Fragile X syndrome can include developmental delays, social anxiety, and learning disabilities, which vary between individuals.

The Latest from FRAXA

Shionogi Shares Update on Zatolmilast Fragile X Clinical Trials

October 27, 2025

Shionogi shares an update on its zatolmilast Fragile X clinical trials, outlining progress in U.S. studies and next steps in data analysis and evaluation.

Read More »
The Hye Young Lee Lab at UT Health San Antonio – a dynamic team leading cutting-edge gene therapy research for Fragile X syndrome using next-generation mRNA delivery systems.

Gene Therapeutic Development for Fragile X Syndrome

October 27, 2025

Dr. Lee’s team is testing RNA editing gene therapy for Fragile X, aiming to repair FMR1 RNA and restore missing protein — targeted, reversible, promising.

Read More »
Drs. Peng Jin, Zhexing Wen, and Jie Xu

FMRP Regulatory Role in Human Hippocampal Development and Therapeutic Interventions in Fragile X

October 16, 2025

Fragile X syndrome hippocampal organoids show neuron–glia imbalance. This team will map disrupted gene networks and test PDE inhibitors to restore brain function.

Read More »
No event found!

FRAXA's Impact to Date

FRAXA's Interactive Fragile X Timeline

Explore 30 years of outstanding Fragile X research.

$37.7M

Direct Investment in Fragile X Research

46

Teams Actively Researching Fragile X Syndrome

33

Pharmaceutical and Biomedical Partners

655

Fragile X Research Grants Awarded